<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02279719</url>
  </required_header>
  <id_info>
    <org_study_id>BBIHCC-103</org_study_id>
    <secondary_id>BBI608-503-103HCC</secondary_id>
    <nct_id>NCT02279719</nct_id>
  </id_info>
  <brief_title>A Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular Carcinoma</brief_title>
  <official_title>A Phase Ib/II Clinical Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sumitomo Dainippon Pharma Oncology, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sumitomo Dainippon Pharma Oncology, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label, three-arm, phase 1 dose escalation study and phase 2 study of BBI608&#xD;
      in combination with sorafenib, or BBI503 in combination with sorafenib. The study population&#xD;
      is adult patients with advanced hepatocellular carcinoma who have not received systemic&#xD;
      chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open label, three-arm, phase 1 dose escalation study and phase 2 study of BBI608&#xD;
      in combination with sorafenib, or BBI503 in combination with sorafenib. The study population&#xD;
      is adult patients with advanced hepatocellular carcinoma (HCC) who have not received systemic&#xD;
      chemotherapy.&#xD;
&#xD;
      The phase 1 portion will involve dose-escalation of BBI608 administered in combination with a&#xD;
      fixed starting dose of sorafenib (Arm 1), and dose escalation of BBI503 administered in&#xD;
      combination with a fixed starting dose of sorafenib (Arm 2). The fixed starting dose-level of&#xD;
      sorafenib for both arms will be 400 mg twice daily (800 mg total daily dose). Eligible&#xD;
      patients will be randomized to either Arm 1 or Arm 2.&#xD;
&#xD;
      The phase 2 portion will be an open-label, 3-arm, randomized trial of patients with advanced&#xD;
      HCC who have not received prior systemic treatment. Patients will be randomized to receive&#xD;
      either, Arm 1: sorafenib administered in combination with BBI608 (at the RP2D determined for&#xD;
      BBI608 plus sorafenib during the phase 1 portion); Arm 2: sorafenib in combination with&#xD;
      BBI503 (at the RP2D determined for BBI503 plus sorafenib during the phase 1 portion), or Arm&#xD;
      3: sorafenib alone at a starting dose of 400 mg twice daily. The starting dose for sorafenib&#xD;
      is the same for all study arms.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">October 2019</completion_date>
  <primary_completion_date type="Actual">July 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of the Dose Limiting Toxicities for the Napabucasin and Amcasertib Arm in Combination With Sorafenib for Phase IB</measure>
    <time_frame>16 weeks including 2-week Sorafenib run-in period prior to initiation of combination therapy</time_frame>
    <description>To assess the dose limiting toxicities for phase IB</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To Assess the Number of Patients Who Experienced Adverse Events for Phase IB.</measure>
    <time_frame>Adverse events will be assessed at baseline, while the participant is taking drugs, and for 30 days after stopping therapy. It was expected that patients would receive between 4-24 weeks treatment.</time_frame>
    <description>Assessment of safety of either BBI608 or BBI503 given in combination with sorafenib to patients with hepatocellular carcinoma by reporting of adverse events and serious adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determination of the Recommended Phase II Dose for Napabucasin and Amcasertib Arm in Combination With Sorafenib</measure>
    <time_frame>16 weeks including 2-week Sorafenib run-in period prior to initiation of combination therapy</time_frame>
    <description>To determine the recommended phase II dose for Napabucasin and Amcasertib arm in combination with sorafenib</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of Objective Response Rate in the Intent to Treat Population - Phase II</measure>
    <time_frame>Assessment of the preliminary anti-tumor activity by performing tumor assessments at baseline and every 8 weeks after the date of the first dose of protocol therapy</time_frame>
    <description>To evaluate the preliminary anti-tumor activity in patients with advanced hepatocellular carcinoma randomized to receive treatment with sorafenib in combination with Napabucasin or sorafenib in combination with Amcasertib, or sorafenib alone; Napabucasin and Amcasertib will be administered at their respective RP2D dose levels for combination administration with sorafenib, which were determined during the phase Ib portion of the study.&#xD;
The radiologic assessments will be evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and modified RECIST for patients with hepatocellular carcinoma.&#xD;
ORR was defined as the percentage of patients with a best overall response (BOR) of complete response (CR) or partial response (PR), using both RECIST and mRECIST assessment data.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of Disease Control Rate in the Intent to Treat Population- Phase II</measure>
    <time_frame>Assessment of the preliminary anti-tumor activity by performing tumor assessments at baseline and every 8 weeks after the date of the first dose of protocol therapy</time_frame>
    <description>To evaluate the preliminary anti-tumor activity in patients with advanced hepatocellular carcinoma randomized to receive treatment with sorafenib in combination with Napabucasin, sorafenib in combination with Amcasertib*, or sorafenib alone; Napabucasin and Amcasertib will be administered at their respective RP2D dose levels for combination administration with sorafenib, which were determined during the phase Ib portion of the study.&#xD;
The radiologic assessments will be evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and modified RECIST for patients with hepatocellular carcinoma.&#xD;
Disease control rate (DCR), defined as the proportion of patients with best response of complete response (CR), Partial Response (PR), or stable disease (SD)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of the Pharmacokinetic Profile (Maximum Plasma Concentration and Area Under the Curve) of Either Napabucasin or Amcasertib.</measure>
    <time_frame>On Day 15 of the first cycle and Day 15 of the second cycle, prior to dosing and every one hours to 11 hours and 24 hours after first dose</time_frame>
    <description>To determine the pharmacokinetic (PK) profile of napabucasin administered in combination with sorafenib and of amcasertib administered in combination with sorafenib.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the Pharmacodynamic Studies as Well as the Concentration of Study Drug (Either Napabucasin or Amcasertib) in Tumors</measure>
    <time_frame>On day 15 of the second cycle</time_frame>
    <description>To perform biomarker studies for napabucasin administered in combination with sorafenib and for amcasertib administered in combination with sorafenib.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">97</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>BBI608 and Sorafenib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BBI503 and Sorafenib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sorafenib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BBI608</intervention_name>
    <description>BBI608 will be administered in combination with sorafenib at the RP2D determined during the phase 1 dose-escalation portion of study.</description>
    <arm_group_label>BBI608 and Sorafenib</arm_group_label>
    <other_name>Napabucasin</other_name>
    <other_name>BBI-608</other_name>
    <other_name>BB608</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BBI503</intervention_name>
    <description>BBI503 will be administered in combination with sorafenib at the RP2D determined during the phase 1 dose-escalation portion of study.</description>
    <arm_group_label>BBI503 and Sorafenib</arm_group_label>
    <other_name>Amcasertib</other_name>
    <other_name>BBI-503</other_name>
    <other_name>BB503</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib</intervention_name>
    <description>Sorafenib will be administered at a fixed dose of 400 mg twice daily (800 mg total daily dose). Sorafenib should be taken on an empty stomach, one hour prior to or two hours after meals. Sorafenib should not be taken with study drug, and at least 2 hours should separate a dose of sorafenib from a dose of study drug.</description>
    <arm_group_label>BBI503 and Sorafenib</arm_group_label>
    <arm_group_label>BBI608 and Sorafenib</arm_group_label>
    <arm_group_label>Sorafenib</arm_group_label>
    <other_name>Nexavar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. Signed written informed consent must be obtained and documented according to&#xD;
             International Conference on Harmonisation (ICH) and local regulatory requirements&#xD;
&#xD;
          2. Histologically or cytologically confirmed hepatocellular carcinoma that is metastatic,&#xD;
             unresectable, or recurrent.&#xD;
&#xD;
               1. Patients must not be candidates for curative resection&#xD;
&#xD;
               2. Patients who have recurrent disease after having had one or more prior resections&#xD;
                  may be eligible, provided that they are not candidates for further curative&#xD;
                  resection.&#xD;
&#xD;
               3. Patients who have recurrent hepatocellular carcinoma following hepatic&#xD;
                  transplantation are excluded unless the following criteria are met:&#xD;
&#xD;
             i. Transplantation was performed at least 6 months prior to the relapse of HCC. ii.&#xD;
             Patients are on stable immune suppressive therapy with no clinical evidence of&#xD;
             rejection.&#xD;
&#xD;
             iii. Are receiving ≤ 2.5 mg everolimus daily. d. Patients with known HIV infection are&#xD;
             excluded. e. Patients with Hepatitis B are eligible provided there is no active viral&#xD;
             replication. Patients with Hepatitis C who are not on interferon are eligible.&#xD;
&#xD;
          3. Patients who have a diagnosis of hepatocellular carcinoma made through radiologic&#xD;
             imaging may be eligible, provided they meet the criteria according to the American&#xD;
             Association for the Study of Liver Disease, AASLD (Bruix and Sherman, 2005; Bruix and&#xD;
             Sherman, 2011)&#xD;
&#xD;
          4. Patients must be candidates for sorafenib&#xD;
&#xD;
          5. Must have had no previous systemic anti-cancer treatment, though previous&#xD;
             loco-regional therapy is allowed:&#xD;
&#xD;
             a. Prior treatment with any of the following is allowed: trans-arterial embolization,&#xD;
             trans-arterial chemo-embolization, percutaneous ethanol injection, radio-embolization,&#xD;
             radio-frequency ablation, or other ablation techniques.&#xD;
&#xD;
          6. Must be Child-Pugh class A&#xD;
&#xD;
             a. Patients with uncontrolled massive ascites or presence of hepatic encephalopathy&#xD;
             are excluded&#xD;
&#xD;
          7. Must have total serum bilirubin ≤ 3 mg/dl&#xD;
&#xD;
          8. ≥ 18 years of age&#xD;
&#xD;
          9. Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST)&#xD;
             1.1&#xD;
&#xD;
         10. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1&#xD;
&#xD;
         11. Male or female patients of child-producing potential must agree to use contraception&#xD;
             or avoidance of pregnancy measures during the study and for 30 days after the last&#xD;
             BBI608 or BBI503 dose&#xD;
&#xD;
         12. Females of childbearing potential must have a negative serum pregnancy test&#xD;
&#xD;
         13. Aspartate Aminotransferase (AST) and Alanine transaminase (ALT) &lt; 5.0x the upper limit&#xD;
             of normal (ULN)&#xD;
&#xD;
         14. Glomerular filtration rate (GFR) &gt; 45 mL/min/1.73m^2 according to the Cockcroft-Gault&#xD;
             estimation.&#xD;
&#xD;
        13. Hemoglobin ≥ 8.5 mg/dl 14. Absolute neutrophil count ≥ 1.5 x 10^9/L 15. Platelets ≥ 75&#xD;
        x 10^9/L 16. Life expectancy ≥ 3 months&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Previous treatment with sorafenib&#xD;
&#xD;
          2. Patients with known hypersensitivity to sorafenib or any other component of sorafenib.&#xD;
&#xD;
          3. Previous systemic anti-vascular endothelial growth factor (VEGF) or any prior systemic&#xD;
             anti-cancer therapy, including prior treatment with systemic agents such as&#xD;
             regorafenib, ramucirumab, pazopanib, or experimental agents such as brivanib.&#xD;
&#xD;
          4. Have had a surgical procedure requiring general anesthesia or inpatient&#xD;
             hospitalization for recovery less than 4 weeks prior to beginning protocol therapy.&#xD;
&#xD;
          5. Have had a loco-regional procedure for the treatment of hepatocellular carcinoma (such&#xD;
             as a percutaneous, trans-arterial, or radio-ablative procedure) less than 4 weeks&#xD;
             prior to beginning protocol therapy. Protocol therapy may begin a minimum of 4 weeks&#xD;
             after such a procedure provided the following criteria are met:&#xD;
&#xD;
               1. There is progression of disease documented by RECIST 1.1&#xD;
&#xD;
               2. All adverse events from the procedure have resolved or have been deemed&#xD;
                  irreversible and the patient meets inclusion criteria.&#xD;
&#xD;
          6. Any known symptomatic or untreated brain metastases requiring increase of steroid dose&#xD;
             within 2 weeks prior to starting on study. Patients with treated brain metastases must&#xD;
             be stable for 4 weeks after completion of that treatment. Patients must have no&#xD;
             clinical symptoms from brain metastases and must be either off steroids or on a stable&#xD;
             dose of steroids for at least 2 weeks prior to protocol enrollment. Patients with&#xD;
             known leptomeningeal metastases are excluded, even if treated.&#xD;
&#xD;
          7. Pregnant or breastfeeding&#xD;
&#xD;
          8. Significant gastrointestinal disorder(s), (e.g., Crohn's disease, ulcerative colitis,&#xD;
             extensive gastric and small intestine resection) such that, in the opinion of the&#xD;
             treating investigator, absorption of oral medications may be impaired.&#xD;
&#xD;
          9. Unable or unwilling to swallow BBI608, BBI503, or sorafenib capsules or tablets&#xD;
&#xD;
         10. Uncontrolled inter-current illness including, but not limited to: ongoing or active&#xD;
             infection, clinically significant non-healing or healing wounds, symptomatic&#xD;
             congestive heart failure, unstable angina pectoris, cardiac arrhythmia, significant&#xD;
             pulmonary disease (shortness of breath at rest or mild exertion), or uncontrolled&#xD;
             infection or psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements (e.g. no reliable transportation).&#xD;
&#xD;
         11. Subjects with a history of another primary cancer, with the exception of: a)&#xD;
             curatively resected non-melanoma skin cancer; b) curatively treated cervical carcinoma&#xD;
             in situ; or c) other primary solid tumor with no known active disease present that, in&#xD;
             the opinion of the investigator, will not affect patient outcome in the setting of&#xD;
             current hepatocellular carcinoma diagnosis.&#xD;
&#xD;
         12. Abnormal ECGs which are clinically significant such as QT prolongation (QTc &gt; 480&#xD;
             msec), clinically significant cardiac enlargement or hypertrophy, new bundle branch&#xD;
             block, or signs of active ischemia. Patients with evidence of prior infarction who are&#xD;
             New York Heart Association (NYHA) functional classes II, III, or IV are excluded, as&#xD;
             are patients with marked arrhythmias such as Wolff Parkinson White pattern or complete&#xD;
             atrioventricular (AV) dissociation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Banner MD Anderson Cancer Center</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern California Research Center</name>
      <address>
        <city>Coronado</city>
        <state>California</state>
        <zip>92118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Center Associates for Research and Excellence, Inc. (Ccare)</name>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <zip>92024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USC Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USOR - Rocky Mountain Cancer Centers</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Health Medical Group Oncology, LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Piedmont Cancer Institute, P.C.</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30318</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute of Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norton Cancer Institute</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minnesota Oncology Hematology, P.A.</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansas City Research Institure</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USOR - Comprehensive Cancer Centers of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Valley Hospital Luckow Pavilion</name>
      <address>
        <city>Paramus</city>
        <state>New Jersey</state>
        <zip>07652</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USOR - New York Oncology Hematology</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester, Wilmot Cancer Institute</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolinas Health Care System</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest Baptist Health</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati, Vontz Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Drexel University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USOR - Texas Oncology, Austin Midtown</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-Baylor Charles A. Sammons Cancer Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - El Paso Cancer Treatment Center Joe Battle</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79938</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USOR - Texas Oncology, Fort Worth 12th Ave</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Consultants</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-McAllen South Second Street</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USOR - Texas Oncology, Tyler</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology and Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <zip>24014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>October 24, 2014</study_first_submitted>
  <study_first_submitted_qc>October 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2014</study_first_posted>
  <results_first_submitted>June 3, 2021</results_first_submitted>
  <results_first_submitted_qc>August 12, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 9, 2021</results_first_posted>
  <last_update_submitted>August 12, 2021</last_update_submitted>
  <last_update_submitted_qc>August 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 3, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/19/NCT02279719/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 10, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/19/NCT02279719/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Experimental Napabucasin+Sorafenib Phase IB Dose- Level 1</title>
          <description>Napabucasin will be administered orally twice daily in combination with sorafenib. The dose of Napabucasin will be 160 mg twice daily Sorafenib will be administered at a fixed dose of 400 mg twice daily (800 mg total daily dose). This dose of sorafenib will be the same for each arm and for each dose-level cohort. Sorafenib should be taken on an empty stomach, one hour prior to or two hours after meals. Sorafenib should not be taken with study drug, and at least 2 hours should separate a dose of sorafenib from a dose of study drug.</description>
        </group>
        <group group_id="P2">
          <title>Experimental Napabucasin+Sorafenib Phase IB Dose-Level 2</title>
          <description>Napabucasin will be administered orally twice daily in combination with sorafenib. The dose of Napabucasin will be 240 mg twice daily Sorafenib will be administered at a fixed dose of 400 mg twice daily (800 mg total daily dose). This dose of sorafenib will be the same for each arm and for each dose-level cohort. Sorafenib should be taken on an empty stomach, one hour prior to or two hours after meals. Sorafenib should not be taken with study drug, and at least 2 hours should separate a dose of sorafenib from a dose of study drug.</description>
        </group>
        <group group_id="P3">
          <title>Experimental Amcasertib +Sorafenib Phase IB Dose- Level 1</title>
          <description>Amcasertib will be administered orally daily in combination with sorafenib. The dose of Amcasertib to be administered will be 100mg once daily. Sorafenib will be administered at a fixed dose of 400 mg twice daily (800 mg total daily dose). This dose of sorafenib will be the same for each arm and for each dose-level cohort. Sorafenib should be taken on an empty stomach, one hour prior to or two hours after meals. Sorafenib should not be taken with study drug, and at least 2 hours should separate a dose of sorafenib from a dose of study drug.</description>
        </group>
        <group group_id="P4">
          <title>Experimental Amcasertib+Sorafenib Phase IB Dose-Level 2</title>
          <description>Amcasertib will be administered orally daily in combination with sorafenib. The dose of Amcasertib to be administered will be 200mg once daily. Sorafenib will be administered at a fixed dose of 400 mg twice daily (800 mg total daily dose). This dose of sorafenib will be the same for each arm and for each dose-level cohort. Sorafenib should be taken on an empty stomach, one hour prior to or two hours after meals. Sorafenib should not be taken with study drug, and at least 2 hours should separate a dose of sorafenib from a dose of study drug.</description>
        </group>
        <group group_id="P5">
          <title>Experimental Napabucasin+Sorafenib Phase II</title>
          <description>Phase II Napabucasin will be administered in combination with sorafenib at the RP2D determined during the phase 1 dose-escalation portion of study. Sorafenib will be administered at a fixed dose of 400 mg twice daily (800 mg total daily dose). Sorafenib should be taken on an empty stomach, one hour prior to or two hours after meals. Sorafenib should not be taken with study drug, and at least 2 hours should separate a dose of sorafenib from a dose of study drug.</description>
        </group>
        <group group_id="P6">
          <title>Experimental Amcasertib+Sorafenib Phase II</title>
          <description>Phase II Amcasertib will be administered in combination with sorafenib at the RP2D determined during the phase 1 dose-escalation portion of study. Sorafenib will be administered at a fixed dose of 400 mg twice daily (800 mg total daily dose). Sorafenib should be taken on an empty stomach, one hour prior to or two hours after meals. Sorafenib should not be taken with study drug, and at least 2 hours should separate a dose of sorafenib from a dose of study drug.</description>
        </group>
        <group group_id="P7">
          <title>Sorafenib Phase II</title>
          <description>Phase II Sorafenib will be administered at a fixed dose of 400 mg twice daily (800 mg total daily dose). Sorafenib should be taken on an empty stomach, one hour prior to or two hours after meals. Sorafenib should not be taken with study drug, and at least 2 hours should separate a dose of sorafenib from a dose of study drug.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="28"/>
                <participants group_id="P6" count="10"/>
                <participants group_id="P7" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="25"/>
                <participants group_id="P6" count="10"/>
                <participants group_id="P7" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Patients randomized but never treated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Experimental Napabucasin +Sorafenib Phase IB- Dose Level 1</title>
          <description>Napabucasin will be administered orally twice daily in combination with sorafenib.&#xD;
The dose of Napabucasin will be 160 mg twice daily Sorafenib will be administered at a fixed dose of 400 mg twice daily (800 mg total daily dose). This dose of sorafenib will be the same for each arm and for each dose-level cohort. Sorafenib should be taken on an empty stomach, one hour prior to or two hours after meals. Sorafenib should not be taken with study drug, and at least 2 hours should separate a dose of sorafenib from a dose of study drug.</description>
        </group>
        <group group_id="B2">
          <title>Experimental Napabucasin +Sorafenib Phase IB- Dose Level 2</title>
          <description>Napabucasin will be administered orally twice daily in combination with sorafenib.&#xD;
The dose of Napabucasin will be 240 mg twice daily Sorafenib will be administered at a fixed dose of 400 mg twice daily (800 mg total daily dose). This dose of sorafenib will be the same for each arm and for each dose-level cohort. Sorafenib should be taken on an empty stomach, one hour prior to or two hours after meals. Sorafenib should not be taken with study drug, and at least 2 hours should separate a dose of sorafenib from a dose of study drug.</description>
        </group>
        <group group_id="B3">
          <title>Experimental Amcasertib +Sorafenib Phase IB- Dose Level 1</title>
          <description>Amcasertib will be administered orally daily in combination with sorafenib. The dose of Amcasertib to be administered will be 100mg once daily. Sorafenib will be administered at a fixed dose of 400 mg twice daily (800 mg total daily dose). This dose of sorafenib will be the same for each arm and for each dose-level cohort. Sorafenib should be taken on an empty stomach, one hour prior to or two hours after meals. Sorafenib should not be taken with study drug, and at least 2 hours should separate a dose of sorafenib from a dose of study drug</description>
        </group>
        <group group_id="B4">
          <title>Experimental Amcasertib +Sorafenib Phase IB- Dose Level 2</title>
          <description>Amcasertib will be administered orally daily in combination with sorafenib. The dose of Amcasertib to be administered will be 200mg once daily. Sorafenib will be administered at a fixed dose of 400 mg twice daily (800 mg total daily dose). This dose of sorafenib will be the same for each arm and for each dose-level cohort. Sorafenib should be taken on an empty stomach, one hour prior to or two hours after meals. Sorafenib should not be taken with study drug, and at least 2 hours should separate a dose of sorafenib from a dose of study drug.</description>
        </group>
        <group group_id="B5">
          <title>Experimental Napabucasin +Sorafenib Phase II</title>
          <description>Phase II Napabucasin will be administered in combination with sorafenib at the RP2D determined during the phase 1 dose-escalation portion of study. Sorafenib will be administered at a fixed dose of 400 mg twice daily (800 mg total daily dose). Sorafenib should be taken on an empty stomach, one hour prior to or two hours after meals. Sorafenib should not be taken with study drug, and at least 2 hours should separate a dose of sorafenib from a dose of study drug.</description>
        </group>
        <group group_id="B6">
          <title>Experimental Amcasertib +Sorafenib Phase II</title>
          <description>Phase II Amcasertib will be administered in combination with sorafenib at the RP2D determined during the phase 1 dose-escalation portion of study. Sorafenib will be administered at a fixed dose of 400 mg twice daily (800 mg total daily dose). Sorafenib should be taken on an empty stomach, one hour prior to or two hours after meals. Sorafenib should not be taken with study drug, and at least 2 hours should separate a dose of sorafenib from a dose of study drug.</description>
        </group>
        <group group_id="B7">
          <title>Sorafenib Phase II</title>
          <description>Phase II Sorafenib will be administered at a fixed dose of 400 mg twice daily (800 mg total daily dose). Sorafenib should be taken on an empty stomach, one hour prior to or two hours after meals. Sorafenib should not be taken with study drug, and at least 2 hours should separate a dose of sorafenib from a dose of study drug.</description>
        </group>
        <group group_id="B8">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="4"/>
            <count group_id="B4" value="9"/>
            <count group_id="B5" value="28"/>
            <count group_id="B6" value="10"/>
            <count group_id="B7" value="31"/>
            <count group_id="B8" value="97"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.4" spread="5.22"/>
                    <measurement group_id="B2" value="70.8" spread="4.42"/>
                    <measurement group_id="B3" value="55.0" spread="22.20"/>
                    <measurement group_id="B4" value="60.6" spread="5.22"/>
                    <measurement group_id="B5" value="64.1" spread="8.72"/>
                    <measurement group_id="B6" value="68.4" spread="9.98"/>
                    <measurement group_id="B7" value="67.7" spread="8.73"/>
                    <measurement group_id="B8" value="65.7" spread="9.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="7"/>
                    <measurement group_id="B8" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="24"/>
                    <measurement group_id="B6" value="7"/>
                    <measurement group_id="B7" value="24"/>
                    <measurement group_id="B8" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="9"/>
                    <measurement group_id="B8" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="18"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="19"/>
                    <measurement group_id="B8" value="66"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Assessment of the Dose Limiting Toxicities for the Napabucasin and Amcasertib Arm in Combination With Sorafenib for Phase IB</title>
        <description>To assess the dose limiting toxicities for phase IB</description>
        <time_frame>16 weeks including 2-week Sorafenib run-in period prior to initiation of combination therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Napabucasin+Sorafenib Phase IB- Dose Level 1</title>
            <description>Napabucasin will be administered orally twice daily in combination with sorafenib. The dose of Napabucasin to be administered will be 160 mg twice daily. The patients are considered evaluable for the determination dose level toxicities and determination of dose escalation if they have been exposed to at least 28 days of continues daily administration of Napabucasin in combination with sorafenib at a compliance level of at least 80% Sorafenib will be administered at a fixed dose of 400 mg twice daily (800 mg total daily dose).</description>
          </group>
          <group group_id="O2">
            <title>Napabucasin+Sorafenib Phase IB- Dose Level 2</title>
            <description>Napabucasin will be administered orally twice daily in combination with sorafenib. The dose of Napabucasin to be administered will be 240 mg twice daily. The patients are considered evaluable for the determination dose level toxicities and determination of dose escalation if they have been exposed to at least 28 days of continues daily administration of Napabucasin in combination with sorafenib at a compliance level of at least 80% Sorafenib will be administered at a fixed dose of 400 mg twice daily (800 mg total daily dose).</description>
          </group>
          <group group_id="O3">
            <title>Amcasertib+Sorafenib Phase IB- Dose Level 1</title>
            <description>Amcasetib will be administered orally once daily in combination with sorafenib. The dose of Amcasertib to be administered will be 100mg once daily. The patients are considered evaluable for the determination dose level toxicities and determination of dose escalation if they have been exposed to at least 28 days of continues daily administration of Amcasertib in combination with sorafenib at a compliance level of at least 80% Sorafenib will be administered at a fixed dose of 400 mg twice daily (800 mg total daily dose).</description>
          </group>
          <group group_id="O4">
            <title>Amcasertib+ Sorafenib Phase IB Dose Level 2</title>
            <description>Amcasertib will be administered orally once daily in combination with sorafenib. The dose of Amcasertib will be 200mg once daily. The patients are considered evaluable for the determination dose level toxicities and determination of dose escalation if they have been exposed to at least 28 days of continues daily administration of Amcasertib in combination with sorafenib at a compliance level of at least 80% Sorafenib will be administered at a fixed dose of 400 mg twice daily (800 mg total daily dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of the Dose Limiting Toxicities for the Napabucasin and Amcasertib Arm in Combination With Sorafenib for Phase IB</title>
          <description>To assess the dose limiting toxicities for phase IB</description>
          <units>Dose limiting toxicities</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>To Assess the Number of Patients Who Experienced Adverse Events for Phase IB.</title>
        <description>Assessment of safety of either BBI608 or BBI503 given in combination with sorafenib to patients with hepatocellular carcinoma by reporting of adverse events and serious adverse events</description>
        <time_frame>Adverse events will be assessed at baseline, while the participant is taking drugs, and for 30 days after stopping therapy. It was expected that patients would receive between 4-24 weeks treatment.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Napabucasin+Sorafenib Phase IB- Dose Level 1</title>
            <description>Napabucasin will be administered orally twice daily in combination with sorafenib. The dose of Napabucasin to be administered will be 160mg twice daily. The patients are considered evaluable for the determination dose level toxicities and determination of dose escalation if they have been exposed to at least 28 days of continues daily administration of Napabucasin in combination with sorafenib at a compliance level of at least 80% Sorafenib will be administered at a fixed dose of 400 mg twice daily (800 mg total daily dose).</description>
          </group>
          <group group_id="O2">
            <title>Napabucasin+Sorafenib Phase IB - Dose Level 2</title>
            <description>Napabucasin will be administered orally twice daily in combination with sorafenib. The dose of Napabucasin to be administered will be 240 mg twice daily. The patients are considered evaluable for the determination dose level toxicities and determination of dose escalation if they have been exposed to at least 28 days of continues daily administration of Napabucasin in combination with sorafenib at a compliance level of at least 80% Sorafenib will be administered at a fixed dose of 400 mg twice daily (800 mg total daily dose).</description>
          </group>
          <group group_id="O3">
            <title>Amcasertib +Sorafenib Phase IB- Dose Level 1</title>
            <description>Amcasetib will be administered orally once daily in combination with sorafenib. The dose of Amcasertib to be administered will be 100mg once daily. The patients are considered evaluable for the determination dose level toxicities and determination of dose escalation if they have been exposed to at least 28 days of continues daily administration of Amcasertib in combination with sorafenib at a compliance level of at least 80% Sorafenib will be administered at a fixed dose of 400 mg twice daily (800 mg total daily dose).</description>
          </group>
          <group group_id="O4">
            <title>Amcasertib+ Sorafenib Phase IB- Dose Level 2</title>
            <description>Amcasetib will be administered orally once daily in combination with sorafenib. The dose of Amcasertib to be administered will be 200mg once daily. The patients are considered evaluable for the determination dose level toxicities and determination of dose escalation if they have been exposed to at least 28 days of continues daily administration of Amcasertib in combination with sorafenib at a compliance level of at least 80% Sorafenib will be administered at a fixed dose of 400 mg twice daily (800 mg total daily dose).</description>
          </group>
        </group_list>
        <measure>
          <title>To Assess the Number of Patients Who Experienced Adverse Events for Phase IB.</title>
          <description>Assessment of safety of either BBI608 or BBI503 given in combination with sorafenib to patients with hepatocellular carcinoma by reporting of adverse events and serious adverse events</description>
          <units>count of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Patients with TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients with TEAEs CTCAE ≥Grade 3 TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients with serious TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients with TEAEs leading to treatment discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients with TEAEs leading to Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients with TEAEs leading to Napabucasin reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients with TEAEs leading to Amcasertib dose reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients with TEAEs leading to Napabucasin dose held</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients with TEAEs leading to Amcasertib dose held</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Determination of the Recommended Phase II Dose for Napabucasin and Amcasertib Arm in Combination With Sorafenib</title>
        <description>To determine the recommended phase II dose for Napabucasin and Amcasertib arm in combination with sorafenib</description>
        <time_frame>16 weeks including 2-week Sorafenib run-in period prior to initiation of combination therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Napabucasin+Sorafenib Phase IB</title>
            <description>Napabucasin will be administered orally twice daily in combination with sorafenib. The dose of Napabucasin to be administered will depend on the assigned dose-level cohort. The patients are considered evaluable for the determination dose level toxicities and determination of dose escalation if they have been exposed to at least 28 days of continues daily administration of Napabucasin in combination with sorafenib at a compliance level of at least 80% Sorafenib will be administered at a fixed dose of 400 mg twice daily (800 mg total daily dose).</description>
          </group>
          <group group_id="O2">
            <title>Amcasertib+ Sorafenib Phase IB</title>
            <description>Amcasertib will be administered orally daily in combination with sorafenib. The dose of Amcasertib to be administered will depend on the assigned dose-level cohort. The patients are considered evaluable for the determination dose level toxicities and determination of dose escalation if they have been exposed to at least 28 days of continues daily administration of Amcasertib in combination with sorafenib at a compliance level of at least 80% Sorafenib will be administered at a fixed dose of 400 mg twice daily (800 mg total daily dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Determination of the Recommended Phase II Dose for Napabucasin and Amcasertib Arm in Combination With Sorafenib</title>
          <description>To determine the recommended phase II dose for Napabucasin and Amcasertib arm in combination with sorafenib</description>
          <units>mg</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Recommended Dose of Napabucasin for phase II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="480"/>
                    <measurement group_id="O2" value="NA">The recommended dose for Napabucasin and Amcasertib has been evaluated by arm only for phase IB.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Recommended dose of Amcasertib for Phase II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">The recommended dose for Napabucasin and Amcasertib has been evaluated by arm only for phase IB.</measurement>
                    <measurement group_id="O2" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Assessment of Objective Response Rate in the Intent to Treat Population - Phase II</title>
        <description>To evaluate the preliminary anti-tumor activity in patients with advanced hepatocellular carcinoma randomized to receive treatment with sorafenib in combination with Napabucasin or sorafenib in combination with Amcasertib, or sorafenib alone; Napabucasin and Amcasertib will be administered at their respective RP2D dose levels for combination administration with sorafenib, which were determined during the phase Ib portion of the study.&#xD;
The radiologic assessments will be evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and modified RECIST for patients with hepatocellular carcinoma.&#xD;
ORR was defined as the percentage of patients with a best overall response (BOR) of complete response (CR) or partial response (PR), using both RECIST and mRECIST assessment data.</description>
        <time_frame>Assessment of the preliminary anti-tumor activity by performing tumor assessments at baseline and every 8 weeks after the date of the first dose of protocol therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental Napabucasin +Sorafenib Phase II</title>
            <description>Phase II Napabucasin will be administered in combination with sorafenib at the RP2D determined during the phase 1 dose-escalation portion of study. Sorafenib will be administered at a fixed dose of 400 mg twice daily (800 mg total daily dose). Sorafenib should be taken on an empty stomach, one hour prior to or two hours after meals. Sorafenib should not be taken with study drug, and at least 2 hours should separate a dose of sorafenib from a dose of study drug.</description>
          </group>
          <group group_id="O2">
            <title>Experimental Amcasertib+Sorafenib Phase II</title>
            <description>Phase II Amcasertib will be administered in combination with sorafenib at the RP2D determined during the phase 1 dose-escalation portion of study. Sorafenib will be administered at a fixed dose of 400 mg twice daily (800 mg total daily dose). Sorafenib should be taken on an empty stomach, one hour prior to or two hours after meals. Sorafenib should not be taken with study drug, and at least 2 hours should separate a dose of sorafenib from a dose of study drug</description>
          </group>
          <group group_id="O3">
            <title>Sorafenib Phase II</title>
            <description>Phase II Sorafenib will be administered at a fixed dose of 400 mg twice daily (800 mg total daily dose). Sorafenib should be taken on an empty stomach, one hour prior to or two hours after meals. Sorafenib should not be taken with study drug, and at least 2 hours should separate a dose of sorafenib from a dose of study drug</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Objective Response Rate in the Intent to Treat Population - Phase II</title>
          <description>To evaluate the preliminary anti-tumor activity in patients with advanced hepatocellular carcinoma randomized to receive treatment with sorafenib in combination with Napabucasin or sorafenib in combination with Amcasertib, or sorafenib alone; Napabucasin and Amcasertib will be administered at their respective RP2D dose levels for combination administration with sorafenib, which were determined during the phase Ib portion of the study.&#xD;
The radiologic assessments will be evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and modified RECIST for patients with hepatocellular carcinoma.&#xD;
ORR was defined as the percentage of patients with a best overall response (BOR) of complete response (CR) or partial response (PR), using both RECIST and mRECIST assessment data.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Assessment of Objective Response Rate based on RECIST 1.1 criteria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" lower_limit="0.1" upper_limit="18.3"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="30.8"/>
                    <measurement group_id="O3" value="9.7" lower_limit="2.0" upper_limit="25.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Assessment of Objective Response Rate based on mRECIST 1.1 criteria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" lower_limit="0.1" upper_limit="18.3"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="30.8"/>
                    <measurement group_id="O3" value="6.5" lower_limit="0.8" upper_limit="21.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Assessment of Disease Control Rate in the Intent to Treat Population- Phase II</title>
        <description>To evaluate the preliminary anti-tumor activity in patients with advanced hepatocellular carcinoma randomized to receive treatment with sorafenib in combination with Napabucasin, sorafenib in combination with Amcasertib*, or sorafenib alone; Napabucasin and Amcasertib will be administered at their respective RP2D dose levels for combination administration with sorafenib, which were determined during the phase Ib portion of the study.&#xD;
The radiologic assessments will be evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and modified RECIST for patients with hepatocellular carcinoma.&#xD;
Disease control rate (DCR), defined as the proportion of patients with best response of complete response (CR), Partial Response (PR), or stable disease (SD)</description>
        <time_frame>Assessment of the preliminary anti-tumor activity by performing tumor assessments at baseline and every 8 weeks after the date of the first dose of protocol therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental Napabucasin +Sorafenib Phase II</title>
            <description>Phase II Napabucasin will be administered in combination with sorafenib at the RP2D determined during the phase 1 dose-escalation portion of study. Sorafenib will be administered at a fixed dose of 400 mg twice daily (800 mg total daily dose). Sorafenib should be taken on an empty stomach, one hour prior to or two hours after meals. Sorafenib should not be taken with study drug, and at least 2 hours should separate a dose of sorafenib from a dose of study drug.</description>
          </group>
          <group group_id="O2">
            <title>Experimental Amcasertib+Sorafenib Phase II</title>
            <description>Phase II Amcasertib will be administered in combination with sorafenib at the RP2D determined during the phase 1 dose-escalation portion of study. Sorafenib will be administered at a fixed dose of 400 mg twice daily (800 mg total daily dose). Sorafenib should be taken on an empty stomach, one hour prior to or two hours after meals. Sorafenib should not be taken with study drug, and at least 2 hours should separate a dose of sorafenib from a dose of study drug</description>
          </group>
          <group group_id="O3">
            <title>Sorafenib Phase II</title>
            <description>Phase II Sorafenib will be administered at a fixed dose of 400 mg twice daily (800 mg total daily dose). Sorafenib should be taken on an empty stomach, one hour prior to or two hours after meals. Sorafenib should not be taken with study drug, and at least 2 hours should separate a dose of sorafenib from a dose of study drug</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Disease Control Rate in the Intent to Treat Population- Phase II</title>
          <description>To evaluate the preliminary anti-tumor activity in patients with advanced hepatocellular carcinoma randomized to receive treatment with sorafenib in combination with Napabucasin, sorafenib in combination with Amcasertib*, or sorafenib alone; Napabucasin and Amcasertib will be administered at their respective RP2D dose levels for combination administration with sorafenib, which were determined during the phase Ib portion of the study.&#xD;
The radiologic assessments will be evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and modified RECIST for patients with hepatocellular carcinoma.&#xD;
Disease control rate (DCR), defined as the proportion of patients with best response of complete response (CR), Partial Response (PR), or stable disease (SD)</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Assessment of Objective Response Rate based on RECIST 1.1 criteria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.7" lower_limit="18.6" upper_limit="55.9"/>
                    <measurement group_id="O2" value="70.0" lower_limit="34.8" upper_limit="93.3"/>
                    <measurement group_id="O3" value="48.4" lower_limit="30.2" upper_limit="66.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Assessment of Objective Response Rate based on mRECIST 1.1 criteria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.7" lower_limit="18.6" upper_limit="55.9"/>
                    <measurement group_id="O2" value="50.0" lower_limit="18.7" upper_limit="81.3"/>
                    <measurement group_id="O3" value="48.4" lower_limit="30.2" upper_limit="66.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of the Pharmacokinetic Profile (Maximum Plasma Concentration and Area Under the Curve) of Either Napabucasin or Amcasertib.</title>
        <description>To determine the pharmacokinetic (PK) profile of napabucasin administered in combination with sorafenib and of amcasertib administered in combination with sorafenib.</description>
        <time_frame>On Day 15 of the first cycle and Day 15 of the second cycle, prior to dosing and every one hours to 11 hours and 24 hours after first dose</time_frame>
        <population>PK parameters were not calculated for this study and are not available. The analyses were not performed as decisions were made to discontinue all clinical development of amcasertib, and of napabucasin for hepatocellular carcinoma.</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental Napabucasin Plus Sorafenib Phase IB- Dose Level 1</title>
            <description>Napabucasin will be administered orally twice daily in combination with sorafenib. The dose of Napabucasin to be administered will be 160mg daily.&#xD;
Sorafenib will be administered at a fixed dose of 400 mg twice daily (800 mg total daily dose). This dose of sorafenib will be the same for each arm and for each dose-level cohort. Sorafenib should be taken on an empty stomach, one hour prior to or two hours after meals. Sorafenib should not be taken with study drug, and at least 2 hours should separate a dose of sorafenib from a dose of study drug</description>
          </group>
          <group group_id="O2">
            <title>Experimental Napabucasin Plus Sorafenib Phase IB- Dose Level 2</title>
            <description>Napabucasin will be administered orally twice daily in combination with sorafenib. The dose of Napabucasin will be 240 mg twice daily Sorafenib will be administered at a fixed dose of 400 mg twice daily (800 mg total daily dose). This dose of sorafenib will be the same for each arm and for each dose-level cohort. Sorafenib should be taken on an empty stomach, one hour prior to or two hours after meals. Sorafenib should not be taken with study drug, and at least 2 hours should separate a dose of sorafenib from a dose of study drug.</description>
          </group>
          <group group_id="O3">
            <title>Experimental Amcsertib Plus Sorafenib Phase IB- Dose Level 1</title>
            <description>Amcasertib will be administered orally daily in combination with sorafenib. The dose of Amcasertib to be administered will be 100mg once daily. Sorafenib will be administered at a fixed dose of 400 mg twice daily (800 mg total daily dose). This dose of sorafenib will be the same for each arm and for each dose-level cohort. Sorafenib should be taken on an empty stomach, one hour prior to or two hours after meals. Sorafenib should not be taken with study drug, and at least 2 hours should separate a dose of sorafenib from a dose of study drug.</description>
          </group>
          <group group_id="O4">
            <title>Experimental Amcasetib Plus Sorafenib Phase IB- Dose Level 2</title>
            <description>Amcasertib will be administered orally daily in combination with sorafenib. The dose of Amcasertib to be administered will be 200mg once daily. Sorafenib will be administered at a fixed dose of 400 mg twice daily (800 mg total daily dose). This dose of sorafenib will be the same for each arm and for each dose-level cohort. Sorafenib should be taken on an empty stomach, one hour prior to or two hours after meals. Sorafenib should not be taken with study drug, and at least 2 hours should separate a dose of sorafenib from a dose of study drug.</description>
          </group>
          <group group_id="O5">
            <title>Experimental Napabucasin Plus Sorafenib Phase II</title>
            <description>Phase II Napabucasin will be administered in combination with sorafenib at the RP2D determined during the phase 1 dose-escalation portion of study. Sorafenib will be administered at a fixed dose of 400 mg twice daily (800 mg total daily dose). Sorafenib should be taken on an empty stomach, one hour prior to or two hours after meals. Sorafenib should not be taken with study drug, and at least 2 hours should separate a dose of sorafenib from a dose of study drug</description>
          </group>
          <group group_id="O6">
            <title>Experimental Amcasertib Plus Sorafenib Phase II</title>
            <description>Phase II Amcasertib will be administered in combination with sorafenib at the RP2D determined during the phase 1 dose-escalation portion of study. Sorafenib will be administered at a fixed dose of 400 mg twice daily (800 mg total daily dose). Sorafenib should be taken on an empty stomach, one hour prior to or two hours after meals. Sorafenib should not be taken with study drug, and at least 2 hours should separate a dose of sorafenib from a dose of study drug.</description>
          </group>
          <group group_id="O7">
            <title>Sorafenib Phase II</title>
            <description>Phase II Sorafenib will be administered at a fixed dose of 400 mg twice daily (800 mg total daily dose). Sorafenib should be taken on an empty stomach, one hour prior to or two hours after meals. Sorafenib should not be taken with study drug, and at least 2 hours should separate a dose of sorafenib from a dose of study drug</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of the Pharmacokinetic Profile (Maximum Plasma Concentration and Area Under the Curve) of Either Napabucasin or Amcasertib.</title>
          <description>To determine the pharmacokinetic (PK) profile of napabucasin administered in combination with sorafenib and of amcasertib administered in combination with sorafenib.</description>
          <population>PK parameters were not calculated for this study and are not available. The analyses were not performed as decisions were made to discontinue all clinical development of amcasertib, and of napabucasin for hepatocellular carcinoma.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of the Pharmacodynamic Studies as Well as the Concentration of Study Drug (Either Napabucasin or Amcasertib) in Tumors</title>
        <description>To perform biomarker studies for napabucasin administered in combination with sorafenib and for amcasertib administered in combination with sorafenib.</description>
        <time_frame>On day 15 of the second cycle</time_frame>
        <population>PD assessments were not performed for this study and are not available. Archival tissue, with raw staining scores, and no correlative analyses with clinical data were performed. Analyses were not performed as decisions were made to discontinue all clinical development of amcasertib, and also to discontinue development of napabucasin for hepatocellular carcinoma.</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental Napabucasin Plus Sorafenib Phase IB- Dose Level 1</title>
            <description>Napabucasin will be administered orally twice daily in combination with sorafenib. The dose of Napabucasin to be administered will be 160mg twice daily.&#xD;
Sorafenib will be administered at a fixed dose of 400 mg twice daily (800 mg total daily dose). This dose of sorafenib will be the same for each arm and for each dose-level cohort. Sorafenib should be taken on an empty stomach, one hour prior to or two hours after meals. Sorafenib should not be taken with study drug, and at least 2 hours should separate a dose of sorafenib from a dose of study drug</description>
          </group>
          <group group_id="O2">
            <title>Experimental Napabucasin Plus Sorafenib Phase IB- Dose Level 2</title>
            <description>Napabucasin will be administered orally twice daily in combination with sorafenib. The dose of Napabucasin will be 240 mg twice daily Sorafenib will be administered at a fixed dose of 400 mg twice daily (800 mg total daily dose). This dose of sorafenib will be the same for each arm and for each dose-level cohort. Sorafenib should be taken on an empty stomach, one hour prior to or two hours after meals. Sorafenib should not be taken with study drug, and at least 2 hours should separate a dose of sorafenib from a dose of study drug.</description>
          </group>
          <group group_id="O3">
            <title>Experimental Amcasertib Plus Sorafenib Phase IB- Dose Level 1</title>
            <description>Amcasertib will be administered orally daily in combination with sorafenib. The dose of Amcasertib to be administered will be 100mg once daily. Sorafenib will be administered at a fixed dose of 400 mg twice daily (800 mg total daily dose). This dose of sorafenib will be the same for each arm and for each dose-level cohort. Sorafenib should be taken on an empty stomach, one hour prior to or two hours after meals. Sorafenib should not be taken with study drug, and at least 2 hours should separate a dose of sorafenib from a dose of study drug.</description>
          </group>
          <group group_id="O4">
            <title>Experimental Amcasertib Plus Sorafenib Phase IB- Dose Level 2</title>
            <description>Amcasertib will be administered orally daily in combination with sorafenib. The dose of Amcasertib to be administered will be 200mg once daily. Sorafenib will be administered at a fixed dose of 400 mg twice daily (800 mg total daily dose). This dose of sorafenib will be the same for each arm and for each dose-level cohort. Sorafenib should be taken on an empty stomach, one hour prior to or two hours after meals. Sorafenib should not be taken with study drug, and at least 2 hours should separate a dose of sorafenib from a dose of study drug.</description>
          </group>
          <group group_id="O5">
            <title>Experimental Napabucasin Plus Sorafenib Phase II</title>
            <description>Phase II Napabucasin will be administered in combination with sorafenib at the RP2D determined during the phase 1 dose-escalation portion of study. Sorafenib will be administered at a fixed dose of 400 mg twice daily (800 mg total daily dose). Sorafenib should be taken on an empty stomach, one hour prior to or two hours after meals. Sorafenib should not be taken with study drug, and at least 2 hours should separate a dose of sorafenib from a dose of study drug.</description>
          </group>
          <group group_id="O6">
            <title>Experimental Amcasertib Plus Sorafenib Phase II</title>
            <description>Phase II Amcasertib will be administered in combination with sorafenib at the RP2D determined during the phase 1 dose-escalation portion of study. Sorafenib will be administered at a fixed dose of 400 mg twice daily (800 mg total daily dose). Sorafenib should be taken on an empty stomach, one hour prior to or two hours after meals. Sorafenib should not be taken with study drug, and at least 2 hours should separate a dose of sorafenib from a dose of study drug.</description>
          </group>
          <group group_id="O7">
            <title>Sorafenib Phase II</title>
            <description>Phase II Sorafenib will be administered at a fixed dose of 400 mg twice daily (800 mg total daily dose). Sorafenib should be taken on an empty stomach, one hour prior to or two hours after meals. Sorafenib should not be taken with study drug, and at least 2 hours should separate a dose of sorafenib from a dose of study drug</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of the Pharmacodynamic Studies as Well as the Concentration of Study Drug (Either Napabucasin or Amcasertib) in Tumors</title>
          <description>To perform biomarker studies for napabucasin administered in combination with sorafenib and for amcasertib administered in combination with sorafenib.</description>
          <population>PD assessments were not performed for this study and are not available. Archival tissue, with raw staining scores, and no correlative analyses with clinical data were performed. Analyses were not performed as decisions were made to discontinue all clinical development of amcasertib, and also to discontinue development of napabucasin for hepatocellular carcinoma.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the date of the first treatment until 30 days of the last administration of the study drug for an average period of 28 weeks. The total period for both phase I and phase II of the study was 5 years.</time_frame>
      <desc>Napabucasin+Sorafenib Phase II:There were 25 who received at least 1 dose.5 discontinued during the Run-inperiod consisting of sorafenib only;total to receive both napabucasin + sorafenib was 20. Amcasertib+Sorafenib Phase II: There were 10 patients and 3 discontinued during the Run-inperiod consisting of sorafenib only;total to receive both amcasertib + sorafenib was 7.Sorafenib Phase II:Patients from napabucasin and amcasertib arms who only received sorafenib were analyzed with sorafenib arm.</desc>
      <group_list>
        <group group_id="E1">
          <title>Experimental Napabucasin+Sorafenib Phase IB- Dose Level 1</title>
          <description>Patients who have received at least one dose of Napabucasin in combination with sorafenib during the phase 1 dose-escalation portion of study. Sorafenib will be administered at a fixed dose of 400 mg twice daily (800 mg total daily dose).</description>
        </group>
        <group group_id="E2">
          <title>Experimental Napabucasin +Sorafenib Phase IB- Dose Level 2</title>
          <description>Patients who have received at least one dose of Napabucasin in combination with sorafenib during the phase 1 dose-escalation portion of study. Sorafenib will be administered at a fixed dose of 400 mg twice daily (800 mg total daily dose).</description>
        </group>
        <group group_id="E3">
          <title>Experimental Amcasertib+Sorafenib Phase IB- Dose Level 1</title>
          <description>Patients who have received at least one dose of Amcasertib in combination with sorafenib during the phase 1 dose-escalation portion of study. Sorafenib will be administered at a fixed dose of 400 mg twice daily (800 mg total daily dose).</description>
        </group>
        <group group_id="E4">
          <title>Experimental Amcasertib+Sorafenib Phase IB- Dose Level 2</title>
          <description>Patients who have received at least one dose of Amcasertib in combination with sorafenib during the phase 1 dose-escalation portion of study. Sorafenib will be administered at a fixed dose of 400 mg twice daily (800 mg total daily dose).</description>
        </group>
        <group group_id="E5">
          <title>Experimental Napabucasin +Sorafenib Phase II</title>
          <description>Phase II: Patients who have received at least one dose of Napabucasin (at the RP2D determined for napabucasin plus sorafenib during the Phase 1b portion) in combination with sorafenib. In the amcasertib + sorafenib arm, there were 10 patients randomized. Of these 10 patients, 3 discontinued during the Run-in period consisting of sorafenib monotherapy; therefore, the total to receive both amcasertib + sorafenib in Phase 2 was 7</description>
        </group>
        <group group_id="E6">
          <title>Experimental Amcasertib +Sorafenib Phase II</title>
          <description>Phase II: Patients who have received at least one dose of amcasertib (at the RP2D determined for amcasertib plus sorafenib during the Phase 1b portion) in combindation with sorafenib. There were 28 total randomized and 25 who received at least 1 dose of study treatment. Of these 25 patients, 5 discontinued during the Run-in period consisting of sorafenib monotherapy; therefore, the total number of patients to receive both napabucasin + sorafenib in Phase 2 was 20</description>
        </group>
        <group group_id="E7">
          <title>Sorafenib Phase II</title>
          <description>Phase II: Patients who have received at least one dose of sorafenib</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="23" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="16" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Acute Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Gastric Hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Esophageal varices</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Acute Focal Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Gastointestinal Hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Small bowel obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Gastroparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Hematemesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia generalized</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Portal Vein Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Hepatic Cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Acute Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Hepatic Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Enterocolitis infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Septic Shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Urinary Track infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>spinal fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myositis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Mature B-Cell Lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Spinal cord compression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Metabolic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Biliary tube displaced</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Bile Sten Occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Altered mental status</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Kidney Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Acute Respiratory Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Pulmonary edema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="20" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="35" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="17" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="18" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="17" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="22" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Aspartate aminotrasnferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Weight Decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="14" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="16" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dry Skin</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Palmar-plantar erythrosaesthesia syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A copy of any proposed publication or disclosure of the results of the Study will be given to Sponsor for review at least thirty (30) days prior to the date of submission for publication ( including abstracts) or of public disclosure ( the review period).</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Matthew Hitron, MD</name_or_title>
      <organization>Sumitomo Dainippon Pharma Oncology</organization>
      <phone>617-674-6800</phone>
      <email>mhitron@bostonbiomedical.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

